| CEO Name | David Loew |
| Nationality | Switzerland |
| Net Worth Estimation | $25 million |
David Loew, CEO of Ipsen S.A., has an estimated net worth of around $25 million USD, primarily derived from executive compensation, long-term equity incentives, and stock holdings in Ipsen and previous companies. His wealth accrues from his leadership roles in major pharmaceutical firms, bonus structures, and strategic equity grants.
David Loew, CEO of Ipsen S.A., has an estimated net worth of $25 million USD, which is 6% of the $500 million USD maximum for pharmaceutical CEOs. His net worth is 2.5 times higher than the $10 million USD minimum in this business category.
Business Category: Pharmaceutical
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 500000000 USD
David Loew Performance in Ipsen S.A.
David Loew, CEO of Ipsen S.A., exemplifies strategic leadership and data-driven decision-making, steering the biopharmaceutical company towards innovation and global expansion. His performance is marked by successful portfolio diversification and enhanced R&D productivity, significantly increasing Ipsen's market value and competitive advantage. Loew's impact is evident in the company's strengthened pipeline, improved operational efficiency, and sustained revenue growth under his tenure.
Latest News
Ipsen S.A. CEO David Loew Leads Strong Growth and Strategic Expansion in 2025
Ipsen reported robust sales growth of 12.1% year-to-date in 2025, upgrading full-year guidance to around 10% growth driven by oncology, rare disease, and neuroscience sectors. CEO David Loew, appointed mid-2020, directs focus on mid-size leadership, oncology pipeline expansion via acquisition of ImCheck Therapeutics, and product innovation while steering clear of gene therapy.
Source: http://www.ipsen.com/press-releases/ipsen-delivers-strong-sales-in-the-first-nine-months-of-2025-and-further-upgrades-its-full-year-guidance/